Simultaneous electrical detection of IL-6 and PCT using a microfluidic biochip platform.

Area of Science:

• Biomedical Engineering
• Clinical Diagnostics
• Biomarker Analysis

Background:

• Sepsis is a leading cause of mortality and healthcare costs in the U.S.
• Current sepsis diagnosis relies on non-specific clinical parameters.
• Biomarkers like Interleukin-6 (IL-6) and Procalcitonin (PCT) show promise for sepsis management.

Purpose of the Study:

• To develop and validate a microfluidic point-of-care (POC) platform for simultaneous detection of IL-6 and PCT.
• To correlate biomarker concentrations with sepsis severity using advanced analytics.
• To improve sepsis diagnosis and prognosis through rapid, multi-parameter testing.

Main Methods:

• Utilized impedance cytometry, microbead immunoassays, and biotin-streptavidin binding.
• Developed a multiplexed immunoassay for simultaneous IL-6 and PCT detection in human plasma.
• Validated the POC system by quantifying biomarker concentrations in samples with varying levels (healthy, medium, high).

Main Results:

• The microfluidic POC system successfully correlated microbead capture to IL-6 and PCT concentrations.
• Demonstrated statistically significant (P < 0.05 to P < 0.00001) detection of IL-6 and PCT across different concentration levels.
• Validated the device's capability for simultaneous, quantitative measurement of key sepsis biomarkers.

Conclusions:

• The developed microfluidic POC platform enables rapid, simultaneous detection of sepsis biomarkers IL-6 and PCT.
• This technology has the potential to significantly aid in the early diagnosis and prognosis of sepsis patients.
• The system's validation supports its application as a POC tool for improving sepsis management strategies.